Clinicopathological analysis revealed marked upregulation of WNT2 and WNT7B in HER2-positive breast cancer, suggesting a potential synergy between WNT signaling and HER2-driven oncogenic pathways. This evidence concerns the gene ERBB2 and breast carcinoma.